ReviewNature medicine2005
T cell vaccines for microbial infections.
Review in Nature medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 215 citations in OpenAlex.
- Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.Nature communications · 2013Trial
- Trial
- Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response.PloS one · 2011Trial
- Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.The Journal of infectious diseases · 2008Trial
- Developing T Cell Epitope-Based Vaccines Against Infection: Challenging but Worthwhile.Vaccines · 2025Review
- Review
- Review
- Design of Cytotoxic T Cell Epitopes by Machine Learning of Human Degrons.ACS central science · 2024Article
- Development of a Novel Vaccine Candidates againstBioMed research international · 2023Article
- Differences in H3K4me3 and chromatin accessibility contribute to altered T-cell receptor signaling in neonatal naïve CD4 T cells.Immunology and cell biology · 2022Article
- Progress towards the Elusive Mastitis Vaccines.Vaccines · 2022Review
- Cellular Immune Response after Vaccination in Patients with Cancer-Review on Past and Present Experiences.Vaccines · 2022Review
- Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.Nanomaterials (Basel, Switzerland) · 2022Review
- Article
- Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure.World journal of gastroenterology · 2021Review
- Article
- Strategy to enhance dendritic cell-mediated DNA vaccination in the lung.Advanced therapeutics · 2021Article
- Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.Clinical & translational immunology · 2021Article
- BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis.Frontiers in immunology · 2021Article
- Development of combination adjuvant for efficient T cell and antibody response induction against protein antigen.PloS one · 2021Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vaccination, or the deliberate induction of protective immunity by administering nonpathogenic forms of a microbe or its antigens to induce a memory immune response, is the world's most cost-effective medical procedure for preventing morbidity and mortality caused by infectious disease. Historically, most vaccines have worked by eliciting long-lived plasma cells. These cells produce antibodies that limit disease by neutralizing a toxin or blocking the spread of the infectious agent. For these 'B cell vaccines,' the immunological marker, or correlate, for protection is the titer of protective antibodies. With the discovery of HIV/AIDS, vaccine development has been confronted by an agent that is not easily blocked by antibody. To overcome this, researchers who are developing HIV/AIDS vaccines have turned to the elicitation of cellular immunity, or 'T cell vaccines,' which recognize and kill infected cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.